Larotrectinib Sulfate Suppliers & Bulk Manufacturers

Available Forms: Capsule / Oral suspension

Available Strengths: 25 mg, 100 mg, 20 mg/mL

Reference Brands: Vitrakvi (USA/EU/LATAM)

Category: Oncology Cancer Care

Product Description:

Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor developed for the treatment of cancers driven by NTRK gene fusions. These gene fusions lead to the production of abnormal TRK proteins that promote uncontrolled cell growth and tumor development. By specifically targeting and inhibiting TRK proteins, larotrectinib helps block the signaling pathways responsible for cancer progression. This targeted mechanism allows the drug to act across different types of solid tumors, regardless of where the cancer started in the body, as long as the tumor carries an NTRK gene fusion.

Clinical studies have demonstrated the effectiveness of larotrectinib in both adult and pediatric patients with a wide range of solid tumors. The therapy has shown meaningful and durable responses, particularly in patients whose cancers are difficult to treat with conventional therapies. In expanded clinical evaluations involving adult patients with TRK fusion sarcomas, larotrectinib has shown promising efficacy while maintaining a manageable safety profile.

Because of its precision-targeted approach, larotrectinib represents an important advancement in modern oncology, supporting the growing role of biomarker-driven treatments in improving outcomes for patients with rare genetic alterations in cancer.